A Business at a Glance
0 of 5 daily views used (5 remaining). Sign up free for 10 daily views, or try AAPL for a full preview.
Aurinia is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. In January 2021, the Company introduced LUPKYNIS® (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis (“LN”). Aurinia is also developing aritinercept, a dual inhibitor of B cell-activating factor (“BAFF”) and a proliferation-inducing ligand (“APRIL”) for the potential treatment of autoimmune diseases. Net Product Sales Aurinia sells LUPKYNIS to two specialty pharmacies and a specialty distributor in the United States (“U.S.”), and Aurinia sells LUPKYNIS inventory to its collaboration partner, Otsuka Pharmaceutical Co., Ltd. (“Otsuka”), for the European and Japanese market. For the year ended December 31, 2025, net product sales were $271.3 million, up 25% compared to $216.2 million in 2024.
| Metric | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|---|
| Revenue | 283M | 283M | 235M | 176M | 134M | - |
| Net Income | 287M | 287M | 5.8M | -78M | -108M | -181M |
| EPS | $2.07 | $2.07 | $0.04 | $-0.54 | $-0.76 | $-1.40 |
| Free Cash Flow | 136M | 136M | 44M | -33M | -80M | -159M |
| ROIC | 50.3% | 62.3% | 1.3% | -17.2% | -24.5% | -40.8% |
| Gross Margin | 88.5% | 88.5% | 88.0% | 91.9% | 95.8% | - |
| Debt/Equity | 0.16 | 0.16 | 0.25 | 0.30 | 0.02 | 0.02 |
| Dividends/Share | $0.00 | - | - | - | - | - |
| Operating Income | 118M | 118M | -4.7M | -92M | -111M | -181M |
| Operating Margin | 41.9% | 41.9% | -2.0% | -52.2% | -83.2% | - |
| ROE | 49.4% | 59.9% | 1.5% | -20.6% | -24.5% | -40.8% |
| Shares Outstanding | 139M | 139M | 144M | 144M | 142M | 129M |
| Metric | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |||
|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||
| Revenue | N/A | N/A | N/A | N/A | 134M | 176M | 235M | 283M | 283M |
| Gross Margin | N/A | N/A | N/A | N/A | 95.8% | 91.9% | 88.0% | 88.5% | 88.5% |
| R&D | 41M | 53M | 50M | 51M | 45M | 50M | 21M | 33M | 33M |
| SG&A | 14M | 22M | 97M | 174M | 196M | 195M | 172M | 102M | 102M |
| EBIT | -55M | -91M | -104M | -181M | -111M | -92M | -4.7M | 118M | 118M |
| Op. Margin | N/A | N/A | N/A | N/A | -83.2% | -52.2% | -2.0% | 41.9% | 41.9% |
| Net Income | -53M | -88M | -103M | -181M | -108M | -78M | 5.8M | 287M | 287M |
| Net Margin | N/A | N/A | N/A | N/A | -80.7% | -44.5% | 2.4% | 101.5% | 101.5% |
| Non-Recurring | 0 | 0 | 0 | 0 | 3.6M | 916K | 23M | 1.6M | 1.6M |
| Returns on Capital | |||||||||
| ROIC | N/A | -40.7% | -29.1% | -40.8% | -24.5% | -17.2% | 1.3% | 62.3% | 50.3% |
| ROE | N/A | -40.7% | -29.1% | -40.8% | -24.5% | -20.6% | 1.5% | 59.9% | 49.4% |
| ROA | -71728.4% | -54.5% | -26.1% | -35.9% | -21.3% | -14.2% | 1.0% | 44.1% | 38.2% |
| Cash Flow | |||||||||
| Op. Cash Flow | -52M | -64M | -70M | -158M | -80M | -33M | 44M | 136M | 136M |
| Free Cash Flow | -52M | -64M | -72M | -159M | -80M | -33M | 44M | 136M | 136M |
| Owner Earnings | -60M | -71M | -89M | -192M | -115M | -90M | -6.7M | 102M | 102M |
| CapEx | 0 | 0 | 1.7M | 1.2M | 0 | 0 | 0 | 0 | 0 |
| Maint. CapEx | 1.3M | 157K | 1.4M | 2.8M | 2.7M | 12M | 19M | 19M | 19M |
| Growth CapEx | N/A | N/A | 304K | 0 | N/A | N/A | N/A | N/A | 0 |
| D&A | 1.3M | 157K | 1.4M | 2.8M | 2.7M | 12M | 19M | 19M | 19M |
| CapEx/OCF | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 0.0% |
| Capital Allocation | |||||||||
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Dividend Yield | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | 0 | 0 | 0 | 0 | 0 | 0 | 40M | 98M | 98M |
| Buyback Yield | N/A | N/A | N/A | N/A | N/A | N/A | 3.0% | 4.4% | 4.4% |
| Stock-Based Comp | 6.9M | 7.4M | 17M | 31M | 32M | 45M | 32M | 15M | 15M |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Balance Sheet | |||||||||
| Net Debt | N/A | N/A | -264M | -438M | -381M | -238M | -265M | -307M | 11M |
| Cash & Equiv. | 118M | 306M | 272M | 232M | 94M | 49M | 83M | 80M | 80M |
| Long-Term Debt | N/A | N/A | N/A | N/A | 0 | 75M | 59M | 52M | 52M |
| Debt/Equity | N/A | 0.09 | 0.02 | 0.02 | 0.02 | 0.30 | 0.25 | 0.16 | 0.16 |
| Interest Coverage | N/A | N/A | N/A | N/A | N/A | -33.0 | -1.0 | 27.4 | 27.4 |
| Equity | N/A | 299M | 408M | 479M | 405M | 378M | 377M | 581M | 581M |
| Total Assets | 74K | 324M | 464M | 543M | 471M | 548M | 551M | 752M | 752M |
| Total Liabilities | N/A | 26M | 56M | 64M | 65M | 170M | 173M | 170M | 170M |
| Intangibles | N/A | 8.9M | 9.3M | 8.4M | 6.4M | 5.0M | 4.4M | 3.8M | 3.8M |
| Retained Earnings | N/A | -472M | -575M | -756M | -864M | -942M | -937M | -649M | -649M |
| Working Capital | N/A | 304M | 387M | 473M | 396M | 348M | 349M | 398M | 398M |
| Current Assets | N/A | 315M | 419M | 513M | 443M | 425M | 447M | 492M | 492M |
| Current Liabilities | N/A | 11M | 32M | 41M | 46M | 77M | 98M | 94M | 94M |
| Per Share Data | |||||||||
| EPS | -0.63 | -0.95 | -0.87 | -1.40 | -0.76 | -0.54 | 0.04 | 2.07 | 2.07 |
| Owner EPS | -0.71 | -0.76 | -0.75 | -1.48 | -0.80 | -0.63 | -0.05 | 0.73 | 0.73 |
| Book Value | N/A | 3.21 | 3.45 | 3.71 | 2.85 | 2.62 | 2.63 | 4.19 | 4.19 |
| Cash Flow/Share | -0.61 | -0.68 | -0.59 | -1.22 | -0.56 | -0.23 | 0.31 | 0.98 | 2.21 |
| Dividends/Share | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 0.00 |
| Shares Out. | 84.3M | 93.0M | 118.0M | 129.3M | 142.3M | 144.5M | 143.8M | 138.7M | 138.7M |
| Valuation | |||||||||
| P/E Ratio | N/A | N/A | N/A | N/A | N/A | N/A | 230.0 | 7.9 | 7.8 |
| P/FCF | N/A | N/A | N/A | N/A | N/A | N/A | 29.8 | 16.6 | 16.4 |
| EV/EBIT | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 18.5 | 18.9 |
| Price/Book | N/A | 6.7 | 4.0 | 6.3 | 1.5 | 3.5 | 3.5 | 3.9 | 3.8 |
| Price/Sales | N/A | N/A | N/A | N/A | 11.1 | 7.6 | 4.0 | 5.0 | 7.9 |
| FCF Yield | -9.0% | -3.2% | -4.4% | -5.3% | -13.5% | -2.5% | 3.4% | 6.0% | 6.1% |
| Market Cap | 575M | 2.0B | 1.6B | 3.0B | 591M | 1.3B | 1.3B | 2.3B | 2.2B |
| Avg. Price | 5.57 | 6.97 | 15.71 | 16.63 | 10.49 | 9.24 | 6.60 | 10.28 | 16.07 |
| Year-End Price | 6.83 | 21.42 | 13.66 | 23.33 | 4.15 | 9.26 | 9.20 | 16.25 | 16.07 |
Aurinia Pharmaceuticals Inc. passes 5 of 9 quality checks, suggesting mixed fundamentals.
Aurinia Pharmaceuticals Inc. trades at 7.8x trailing earnings, compared to its 15-year median P/E of 7.9x, suggesting it is currently Cheap relative to its historical range. On a free-cash-flow basis, the stock trades at 16.4x vs a median of 23.2x. The company's 5-year average gross margin is 91.0%. Total shareholder yield (buybacks) is 4.4%. At current prices, the estimated annualized return to fair value is +189.1%.
Aurinia Pharmaceuticals Inc. (AUPH) has a current P/E ratio of 7.8, compared to its historical median P/E of 7.9. The stock is currently considered Cheap based on its historical valuation range.
Aurinia Pharmaceuticals Inc. (AUPH) has a 5-year average return on invested capital (ROIC) of -3.8%. This is below average and may indicate limited pricing power.
Aurinia Pharmaceuticals Inc. (AUPH) has a market capitalization of $2.2B. It is classified as a mid-cap stock.
Aurinia Pharmaceuticals Inc. (AUPH) does not currently pay a regular dividend. However, the company returns capital to shareholders through share buybacks, with a buyback yield of 4.40%.
Based on historical P/E analysis, Aurinia Pharmaceuticals Inc. (AUPH) appears cheap. The current P/E of 7.8 is 1% below its historical median of 7.9.
Aurinia Pharmaceuticals Inc. (AUPH) operates in the Pharmaceutical Preparations industry, within the Healthcare sector.
Aurinia Pharmaceuticals Inc. (AUPH) reported annual revenue of $283 million in its most recent fiscal year, based on SEC EDGAR filings.
Aurinia Pharmaceuticals Inc. (AUPH) has a net profit margin of 101.5%. This is a strong margin indicating high profitability.
Aurinia Pharmaceuticals Inc. (AUPH) generated $136 million in free cash flow in its most recent fiscal year. Positive free cash flow supports dividends, buybacks, and debt reduction.
Aurinia Pharmaceuticals Inc. (AUPH) has a debt-to-equity ratio of 0.16. This indicates a conservatively financed balance sheet.
Aurinia Pharmaceuticals Inc. (AUPH) reported earnings per share (EPS) of $2.07 in its most recent fiscal year.
Aurinia Pharmaceuticals Inc. (AUPH) has a return on equity (ROE) of 59.9%. This indicates the company generates strong returns for shareholders.
Aurinia Pharmaceuticals Inc. (AUPH) has a 5-year average gross margin of 91.0%. This high margin suggests strong pricing power and a potential competitive moat.
The Ledger Terminal provides 8 years of financial data for Aurinia Pharmaceuticals Inc. (AUPH), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
Aurinia Pharmaceuticals Inc. (AUPH) has a book value per share of $4.19, based on its most recent annual SEC filing.